Tumour markers in prostate cancer III: Biomarkers in urine

Acta Oncologica

Volumn 50, Issue SUPPL. 1, 2011, Pages 85-89

  Roobol, Monique J ^a   Haese, Alexander ^b   Bjartell, Anders ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Sk Å Ne University Hospital Malm Ö   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA MARKER; GLUTATHIONE TRANSFERASE P1; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; MATRIX METALLOPROTEINASE; PROSTATE SPECIFIC ANTIGEN; SARCOSINE;

AREA UNDER THE CURVE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; DNA METHYLATION; FUSION GENE; GLEASON SCORE; GOLPH2 GENE; HUMAN; INTERMETHOD COMPARISON; METABOLOMICS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PCA3 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SPINK1 GENE; TMPRSS2 ERG FUSION GENE; URINALYSIS; WESTERN BLOTTING;

DISEASE PROGRESSION; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79957520906     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.524935     Document Type: Review

References (39)

1. Schr öd er FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360, 1320-8.
2. Roobol MJ, Kerkhof M, Schrö d er FH, Cuzick J, Sasieni P, Hakama M, et al. Prostate cancer mortality reduction by prostate-specifi c antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009;56:584-91.
3. Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, et al. Mortality results from the G ö teborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11:725-32 .
4. Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ. Overdetection, overtreatment and costs in prostate-specifi c antigen screening for prostate cancer. Br J Cancer 2009;101:1833-8.
5. Irani J, Salomon L, Soulié M, Zlotta A, de la Taille A, Dor é B, et al. Urinary/serum prostate-specifi c antigen ratio: Comparison with free/total serum prostate-specifi c antigen ratio in improving prostate cancer detection. Urology 2005;65:533-7. (Pubitemid 40386004)
6. Bolduc S, Lacombe L, Naud A, Gré goire M, Fradet Y, Tremblay RR. Urinary PSA: A potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J 2007;1:377-81.
7. Pannek J, Rittenhouse HG, Evans CL, Finlay JA, Bruzek DJ, Cox JL, et al. Molecular forms of prostate-specifi c antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology 1997;50:715-21. (Pubitemid 27494992)
8. Schostak M, Schwall GP, Poznanovic S, Groebe K, Muller M, Messinger D, et al. Annexin A3 in urine: A highly specifi c noninvasive marker for prostate cancer early detection. J Urol 2009;181:343-53.
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2: 161-74. (Pubitemid 37328786)
10. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, et al. Tumor-specifi c urinary matrix metalloproteinase fi ngerprinting: Identifi cation of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008;14:6610-7.
11. Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010;7:101-9.
12. Lu Q, Zhang J, Allison R, Gay H, Yang WX, Bhowmick NA, et al. Identification of extracellular deltacatenin accumulation for prostate cancer detection. Prostate 2009;69: 411-8.
13. Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 2009;15:4292-8.
14. Hutchinson LM, Chang EL, Becker CM, Ushiyama N, Behonick D, Shih MC, et al. Development of a sensitive and specifi c enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer. Clin Biochem 2005;38:558-71. (Pubitemid 40693471)
15. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006;7:R80.
16. Goo YA, Goodlett DR. Advances in proteomic prostate cancer biomarker discovery. J Prot 2010 E-pub doi:10.1016/j. jprot.2010.04.002.
17. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profi les delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457:910-4.
18. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. Sarcosine in urine after digital rectal exami nation fails as a marker in prostate cancer detection and identifi cation of aggressive tumours. Eur Urol 2010;58: 12-8.
19. Harden SV, Sanderson H, Goodman SN, Partin AA, Walsh PC, Epstein JI, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 2003;95:1634-7. (Pubitemid 37455931)
20. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, et al. Quantitative methylation specifi c polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005;23:6569-75. (Pubitemid 46190250)
21. Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y, Skelton J, et al. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 2008;54:874-82. (Pubitemid 351671598)
22. Payne SR, Serth J, Schostak M, Kamradt J, Strauss A, Thelen P, et al. DNA methylation biomarkers of prostate cancer: Confi rmation of candidates and evidence urine is the most sensitive body fl uid for non-invasive detection. Prostate 2009;69: 1257-69.
23. Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J, et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol 2009;182:1186-93.
24. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95. (Pubitemid 43794421)
25. Vlaeminck-Guillem V, Ruffi on A, Andr é J, Devonec M, Paparel P. Urinary prostate cancer 3 test: Toward the age of reason? Urology 2010;75:447-53.
26. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol 2004;46:182-6. (Pubitemid 38902733)
27. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-5.
28. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.
29. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54:1081-8.
30. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-5. (Pubitemid 46428401)
31. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostatespecifi c antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70. (Pubitemid 41002840)
32. Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RCN, van Leenders GJ, et al. Performance of the Prostate Cancer Antigen3 (PCA3) gene and prostate-specifi c antigen in prescreened men: Exploring the value of PCA3 for a fi rst-line diagnostic test. Eur Urol 2010 Jul 9 [Epub ahead of print] .
33. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predicitve value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010;70:10-6.
34. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008;180: 1975-8, discussion 1978-9.
35. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8. (Pubitemid 47502077)
36. Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, et al. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res 2010;16: 1572-6.
37. Aubin SM, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, et al. Improved prediction of prostate biopsy outcome using PCA3, TMPRSS2:ERG gene fusion and serum PSA. J Urol Suppl 2008;179:725.
38. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al. A fi rst-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-9. (Pubitemid 351206738)
39. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13: 519-28. (Pubitemid 351763901)